Try our beta test site
6 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND LMB-2 immunotoxin [TREATMENT] NOT rituxan [TREATMENT]
Show Display Options
Rank Status Study
1 Completed LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: LMB-2 immunotoxin
2 Completed Immunotoxin in Treating Patients With Leukemia or Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: LMB-2 immunotoxin
3 Withdrawn Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: LMB-2 immunotoxin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Other: pharmacological study
4 Completed
Has Results
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Conditions: Lymphoma;   T-Cell;   Cutaneous
Intervention: Biological: LMB-2
5 Active, not recruiting Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Condition: Adult T-Cell Leukemia (ATL)
Interventions: Drug: LMB-2;   Drug: Fludarabine;   Drug: Cyclophosphamide
6 Completed
Has Results
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphocytic;   Chronic
Intervention: Drug: LMB-2

Study has passed its completion date and status has not been verified in more than two years.